Research ExplorerPublicationsLocal Tumor Control and Patient Outcome Using Stereotactic B...

Local Tumor Control and Patient Outcome Using Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

Standard

Local Tumor Control and Patient Outcome Using Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma : iRECIST as a Potential Substitute for Traditional Criteria. / Vernuccio, Federica; Godfrey, Devon; Meyer, Mathias; Williamson, Hannah V; Salama, Joseph K; Niedzwiecki, Donna; Stephens, Sarah Jo; Ronald, James; Palta, Manisha; Marin, Daniele.

In: AM J ROENTGENOL, Vol. 213, No. 6, 12.2019, p. 1232-1239.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Vernuccio, F, Godfrey, D, Meyer, M, Williamson, HV, Salama, JK, Niedzwiecki, D, Stephens, SJ, Ronald, J, Palta, M & Marin, D 2019, 'Local Tumor Control and Patient Outcome Using Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: iRECIST as a Potential Substitute for Traditional Criteria', AM J ROENTGENOL, vol. 213, no. 6, pp. 1232-1239. https://doi.org/10.2214/AJR.18.20842

APA

Vernuccio, F., Godfrey, D., Meyer, M., Williamson, H. V., Salama, J. K., Niedzwiecki, D., Stephens, S. J., Ronald, J., Palta, M., & Marin, D. (2019). Local Tumor Control and Patient Outcome Using Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: iRECIST as a Potential Substitute for Traditional Criteria. AM J ROENTGENOL, 213(6), 1232-1239. https://doi.org/10.2214/AJR.18.20842

Vancouver

Vernuccio F, Godfrey D, Meyer M, Williamson HV, Salama JK, Niedzwiecki D et al. Local Tumor Control and Patient Outcome Using Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: iRECIST as a Potential Substitute for Traditional Criteria. AM J ROENTGENOL. 2019 Dec;213(6):1232-1239. https://doi.org/10.2214/AJR.18.20842

Bibtex

@article{dd5b54b8f9534dcc9af37a2d83dc2de3,
title = "Local Tumor Control and Patient Outcome Using Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: iRECIST as a Potential Substitute for Traditional Criteria",
abstract = "OBJECTIVE. The purpose of this study was to investigate whether, compared with traditional criteria, the modified Response Evaluation Criteria in Solid Tumors version 1.1 for immune-based therapeutics (iRECIST) improves prediction of local tumor control and survival in patients with hepatocellular carcinoma (HCC) treated with stereotactic body radiotherapy (SBRT). MATERIALS AND METHODS. Fifty-one HCC lesions (mean size, 3.1 cm) treated with SBRT in 41 patients (mean age, 67 years) were retrospectively included. Each patient underwent CT or MRI before SBRT and at least once after SBRT. Best overall response was categorized using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), iRECIST, World Health Organization (WHO) criteria, modified Response Evaluation Criteria in Solid Tumors (mRECIST), and European Association for the Study of the Liver (EASL) criteria. Lesions were then classified as local tumor control (i.e., stable disease, partial response, or complete response) or local treatment failure (i.e., progressive disease) by each tumor response criteria. Proportions of local tumor control were compared using the McNemar exact test. The 1-year overall survival was estimated using the Kaplan-Meier method. RESULTS. The median follow-up after SBRT was 21.0 months. The local tumor control rate was 94.1% (48/51) by iRECIST, 88.2% (45/51) by RECIST 1.1, 72.5% (37/51) by WHO criteria, 80.4% (41/51) by mRECIST, and 72.5% (37/51) by EASL criteria. The local tumor control rate was significantly higher according to iRECIST compared with WHO (p = 0.0010) and EASL (p = 0.0225) criteria. The 1-year survival rate for patients with local tumor control according to iRECIST (86.4%) was higher (although not statistically significant) compared with the 1-year survival rate for patients with local tumor control according to the other response criteria. CONCLUSION. iRECIST may provide more robust interpretation of HCC response after SBRT, yielding improved prediction of local tumor control and 1-year survival rates compared with traditional criteria.",
author = "Federica Vernuccio and Devon Godfrey and Mathias Meyer and Williamson, {Hannah V} and Salama, {Joseph K} and Donna Niedzwiecki and Stephens, {Sarah Jo} and James Ronald and Manisha Palta and Daniele Marin",
year = "2019",
month = dec,
doi = "10.2214/AJR.18.20842",
language = "English",
volume = "213",
pages = "1232--1239",
journal = "AM J ROENTGENOL",
issn = "0361-803X",
publisher = "American Roentgen Ray Society",
number = "6",

}

RIS

TY - JOUR

T1 - Local Tumor Control and Patient Outcome Using Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

T2 - iRECIST as a Potential Substitute for Traditional Criteria

AU - Vernuccio, Federica

AU - Godfrey, Devon

AU - Meyer, Mathias

AU - Williamson, Hannah V

AU - Salama, Joseph K

AU - Niedzwiecki, Donna

AU - Stephens, Sarah Jo

AU - Ronald, James

AU - Palta, Manisha

AU - Marin, Daniele

PY - 2019/12

Y1 - 2019/12

N2 - OBJECTIVE. The purpose of this study was to investigate whether, compared with traditional criteria, the modified Response Evaluation Criteria in Solid Tumors version 1.1 for immune-based therapeutics (iRECIST) improves prediction of local tumor control and survival in patients with hepatocellular carcinoma (HCC) treated with stereotactic body radiotherapy (SBRT). MATERIALS AND METHODS. Fifty-one HCC lesions (mean size, 3.1 cm) treated with SBRT in 41 patients (mean age, 67 years) were retrospectively included. Each patient underwent CT or MRI before SBRT and at least once after SBRT. Best overall response was categorized using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), iRECIST, World Health Organization (WHO) criteria, modified Response Evaluation Criteria in Solid Tumors (mRECIST), and European Association for the Study of the Liver (EASL) criteria. Lesions were then classified as local tumor control (i.e., stable disease, partial response, or complete response) or local treatment failure (i.e., progressive disease) by each tumor response criteria. Proportions of local tumor control were compared using the McNemar exact test. The 1-year overall survival was estimated using the Kaplan-Meier method. RESULTS. The median follow-up after SBRT was 21.0 months. The local tumor control rate was 94.1% (48/51) by iRECIST, 88.2% (45/51) by RECIST 1.1, 72.5% (37/51) by WHO criteria, 80.4% (41/51) by mRECIST, and 72.5% (37/51) by EASL criteria. The local tumor control rate was significantly higher according to iRECIST compared with WHO (p = 0.0010) and EASL (p = 0.0225) criteria. The 1-year survival rate for patients with local tumor control according to iRECIST (86.4%) was higher (although not statistically significant) compared with the 1-year survival rate for patients with local tumor control according to the other response criteria. CONCLUSION. iRECIST may provide more robust interpretation of HCC response after SBRT, yielding improved prediction of local tumor control and 1-year survival rates compared with traditional criteria.

AB - OBJECTIVE. The purpose of this study was to investigate whether, compared with traditional criteria, the modified Response Evaluation Criteria in Solid Tumors version 1.1 for immune-based therapeutics (iRECIST) improves prediction of local tumor control and survival in patients with hepatocellular carcinoma (HCC) treated with stereotactic body radiotherapy (SBRT). MATERIALS AND METHODS. Fifty-one HCC lesions (mean size, 3.1 cm) treated with SBRT in 41 patients (mean age, 67 years) were retrospectively included. Each patient underwent CT or MRI before SBRT and at least once after SBRT. Best overall response was categorized using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), iRECIST, World Health Organization (WHO) criteria, modified Response Evaluation Criteria in Solid Tumors (mRECIST), and European Association for the Study of the Liver (EASL) criteria. Lesions were then classified as local tumor control (i.e., stable disease, partial response, or complete response) or local treatment failure (i.e., progressive disease) by each tumor response criteria. Proportions of local tumor control were compared using the McNemar exact test. The 1-year overall survival was estimated using the Kaplan-Meier method. RESULTS. The median follow-up after SBRT was 21.0 months. The local tumor control rate was 94.1% (48/51) by iRECIST, 88.2% (45/51) by RECIST 1.1, 72.5% (37/51) by WHO criteria, 80.4% (41/51) by mRECIST, and 72.5% (37/51) by EASL criteria. The local tumor control rate was significantly higher according to iRECIST compared with WHO (p = 0.0010) and EASL (p = 0.0225) criteria. The 1-year survival rate for patients with local tumor control according to iRECIST (86.4%) was higher (although not statistically significant) compared with the 1-year survival rate for patients with local tumor control according to the other response criteria. CONCLUSION. iRECIST may provide more robust interpretation of HCC response after SBRT, yielding improved prediction of local tumor control and 1-year survival rates compared with traditional criteria.

U2 - 10.2214/AJR.18.20842

DO - 10.2214/AJR.18.20842

M3 - SCORING: Journal article

C2 - 31613663

VL - 213

SP - 1232

EP - 1239

JO - AM J ROENTGENOL

JF - AM J ROENTGENOL

SN - 0361-803X

IS - 6

ER -